Jupiter Neurosciences, Inc. Board of Directors

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. The company is also developing JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, it is developing JNS115, which is in Phase II trial for the treatment of Parkinson's disease. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2015 and is headquartered in Jupiter, Florida.

Mr. Christer Rosen

Mr. Christer Rosen

Co-Founder, CEO & Chairman of the Board

Dr. Claes Wahlestedt M.D., Ph.D.

Dr. Claes Wahlestedt M.D., Ph.D.

Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer

Dr. Shaun P. Brothers Ph.D.

Dr. Shaun P. Brothers Ph.D.

Co-Founder, Consulting VP of Scientific Research & Member of Scientific Advisory Board

Mr. Alexander Rosen

Mr. Alexander Rosen

Co-Founder & Chief Administrative Officer

Ms. Alison D. Silva MA, MS

Ms. Alison D. Silva MA, MS

President, Chief Business Officer & Director

Dr. Marshall Hayward Ph.D.

Dr. Marshall Hayward Ph.D.

Co-Founder, Chief Scientific Officer & Director

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.